| Name | Title | Contact Details |
|---|
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.
NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.
BioLabs is the premier co-working space for life science startups.
Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.